Dr. Levi’s clinical research and the implementation of automation in Pap test screening in the Yale cytology division has lead to improvements in the Pap test QA/QC program, cytotechnologist workload, laboratory efficiency, and the turn-around-time of Pap test results. Additionally, her clinical research and the implementation of concurrent molecular testing from liquid-based Pap tests has aided in outpatient gynecologic care and clinical management of infectious vaginitis/cervical disease and human papillomavirus-related cervical dysplasia. Building on her previous experience at a private sector pathology laboratory that studied prostate cancer biomarkers with image analysis, her research interests also include prostate cancer pathology and correlation with image analysis.
A Comparison of the Roche Cobas HPV Test With the Hybrid Capture 2 Test for the Detection of High-Risk Human Papillomavirus Genotypes.
Arch Pathol Lab Med. 2016 Feb;140(2):153-7. doi: 10.5858/arpa.2015-0027-OA.
Detection and genotype of high-risk human papillomavirus in fine-needle aspirates of patients with metastatic squamous cell carcinoma is helpful in determining tumor origin.
Am J Clin Pathol. 2015 May;143(5):694-700. doi: 10.1309/AJCPCZA4PSZCFHQ4.
Prior high-risk human papillomavirus testing and Papanicolaou test results of 70 invasive cervical carcinomas diagnosed in 2012: results of a retrospective multicenter study.
Arch Pathol Lab Med. 2015 Feb;139(2):184-8. doi: 10.5858/arpa.2014-0028-OA.
Methylation of twelve CpGs in human papillomavirus type 16 (HPV16) as an informative biomarker for the triage of women positive for HPV16 infection.
Cancer Prev Res (Phila). 2014 May;7(5):526-33.